Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
Study context
- Population
- Adults with obesity, incl. OSA and/or knee osteoarthritis (OA) protocols (TRIUMPH-1, −2), CVD (TRIUMPH-3), stand-alone OA trial (TRIUMPH-4)over 5800 planned
- Planned comparison
- Weekly subcutaneous retatrutide vs placebo, with healthy diet and physical activity
- Primary endpoint
- Weight management: % change in body weight; OSA: change in Apnea-Hypopnea Index; knee OA: includes change in WOMAC pain subscale score
Methodological details4 phase 3 trials, multicenter, randomized, double-blind, placebo-controlled, basket trial design, Type I error rate controlled at α = 0.05, split between overarching weight management and each basket trial
- 4 phase 3 trials
- Multicenter
- Randomized
- Double-blind
- Placebo-controlled
- Basket trial design
- Type I error rate controlled at α = 0.05, split between overarching weight management and each basket trial
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. Published 15 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →